Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Equivalents (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Cash & Equivalents for 5 consecutive years, with $74.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 30.0% year-over-year to $74.3 million, compared with a TTM value of $74.3 million through Sep 2025, down 30.0%, and an annual FY2024 reading of $110.7 million, changed N/A over the prior year.
  • Cash & Equivalents was $74.3 million for Q3 2025 at Barinthus Biotherapeutics, down from $86.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $243.6 million in Q2 2021 and bottomed at $74.3 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $160.2 million, with a median of $166.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents rose 28.64% in 2022, then crashed 33.82% in 2024.
  • Year by year, Cash & Equivalents stood at $214.1 million in 2021, then fell by 9.19% to $194.4 million in 2022, then fell by 17.53% to $160.3 million in 2023, then plummeted by 30.97% to $110.7 million in 2024, then crashed by 32.88% to $74.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for BRNS at $74.3 million in Q3 2025, $86.3 million in Q2 2025, and $99.1 million in Q1 2025.